- Home
- DMRA vs LILAK Comparison
DMRA vs LILAK Comparison
Compare DMRA & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DMRA | LILAK |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | Bermuda |
| Employees | 7 | 9000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | DMRA | LILAK |
|---|---|---|
| Price | $24.76 | $7.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $43.00 | $8.20 |
| AVG Volume (30 Days) | 398.6K | ★ 1.6M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.50 | $4.75 |
| 52 Week High | $28.76 | $9.13 |
Technical Indicators
Market Signals| Indicator | DMRA | LILAK |
|---|---|---|
| Relative Strength Index (RSI) | 58.86 | 49.03 |
| Support Level | $22.71 | N/A |
| Resistance Level | $27.70 | $8.69 |
| Average True Range (ATR) | 2.23 | 0.39 |
| MACD | 0.41 | -0.02 |
| Stochastic Oscillator | 85.36 | 66.76 |
Price Performance
Historical ComparisonAbout DMRA Damora Therapeutics Inc. Common Stock
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.